SEARCH:   Advanced

Blood, 1 December 2005, Vol. 106, No. 12, pp. 3725-3732. Prepublished online as a Blood First Edition Paper on August 25, 2005; DOI 10.1182/blood-2005-01-0016. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-01-0016v1 106/12/3725    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hiddemann, W. Articles by Unterhalt, M. Search for Related Content PubMed PubMed Citation Articles by Hiddemann, W. Articles by Unterhalt, M. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Wolfgang Hiddemann, Michael Kneba, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Harriet Harder, Susanna Hegewisch-Becker, Thomas Fischer, Martin Kropff, Hans-Edgar Reis, Mathias Freund, Bernhard Wörmann, Roland Fuchs, Manfred Planker, Jörg Schimke, Hartmut Eimermacher, Lorenz Trümper, Ali Aldaoud, Reza Parwaresch, and Michael Unterhalt From the Department of Internal Medicine III, University of Munich, Klinikum Großhadern; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Campus Kiel; Department of Hematology and Oncology, Hospital St Georg, Hamburg; Department of Internal Medicine III, Klinikum Mannheim, University of Heidelberg; Department of Internal Medicine I, University of Homburg/Saar; Department of Internal Medicine I, University of Cologne; Department of Internal Medicine II, Oncology and Hematology, Klinikum Oldenburg; Department of Hematology, Oncology, and Tumor Immunology, Robert-Rössle-Klinik at the Helios Clinic Berlin-Buch, Charité, Campus Berlin-Buch; Department of Oncology, Klinikum Eppendorf, University of Hamburg; Department of Internal Medicine III, University of Mainz; Department of Internal Medicine A, University of Münster; Department of Hematology and Oncology, Kliniken Maria Hilf, Mönchengladbach; Department of Hematology and Oncology, University of Rostock; Department of Internal Medicine, Städtisches Klinikum Braunschweig; Department of Hematology and Oncology, St Antonius Hospital Eschweiler; Department of Hematology and Oncology, Städtische Krankenanstalten Krefeld; Praxis for Hematology and Oncology, Saarbrücken; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen; Department of Hematology and Oncology, University of Göttingen; Praxis for Hematology and Oncology, Leipzig; and Department of Hemato-Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current study, 428 patients with untreated, advanced-stage FL were randomly assigned for therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone (n = 205) or CHOP combined with rituximab (R-CHOP) (n = 223). R-CHOP reduced the relative risk for treatment failure by 60% and significantly prolonged the time to treatment failure (P < .001). In addition, a significantly higher overall response rate (96% vs 90%; P = .011) and a prolonged duration of remission (P = .001) were achieved. In spite of a relatively short observation time, these beneficial effects even translated to superior overall survival (P = .016), with 6 deaths in the R-CHOP group compared with 17 deaths in the CHOP group within the first 3 years. The predominant treatment-related adverse effect was myelosuppression. Severe granulocytopenia was more frequently observed after R-CHOP (63% vs 53%; P = .01). However, severe infections were rare and of similar frequency after R-CHOP and CHOP (5% and 7%). Hence, adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: R-CHOP strikes again with survival benefit in follicular lymphoma Wyndham H. Wilson Blood 2005 106: 3678-3679. [Full Text] [PDF] This article has been cited by other articles: C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al. Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study J. Clin. Oncol., July 20, 2008; 26(21): 3614 - 3620. [Abstract] [Full Text] [PDF] C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui, A. Pileri, M. Boccadoro, F. Ciceri, A. Gallamini, et al. Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey J. Clin. Oncol., July 1, 2008; 26(19): 3166 - 3175. [Abstract] [Full Text] [PDF] A. Hagenbeek, O. Gadeberg, P. Johnson, L. Moller Pedersen, J. Walewski, A. Hellmann, B. K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood, June 15, 2008; 111(12): 5486 - 5495. [Abstract] [Full Text] [PDF] M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab Ann. Onc., June 2, 2008; (2008) mdn172v1. [Abstract] [Full Text] [PDF] J. P. Plastaras, E. Glatstein, and S. J. Schuster Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 655 - 656. [Full Text] [PDF] F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF] E. D. Hsi, R. Steinle, B. Balasa, S. Szmania, A. Draksharapu, B. P. Shum, M. Huseni, D. Powers, A. Nanisetti, Y. Zhang, et al. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma Clin. Cancer Res., May 1, 2008; 14(9): 2775 - 2784. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP Blood, May 1, 2008; 111(9): 4664 - 4667. [Abstract] [Full Text] [PDF] M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage Blood, April 15, 2008; 111(8): 4004 - 4013. [Abstract] [Full Text] [PDF] J. W. Friedberg Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma Haematologica, March 1, 2008; 93(3): 336 - 338. [Full Text] [PDF] R. Pettengell, C. Donatti, P. Hoskin, C. Poynton, P. J. Kettle, B. Hancock, S. Johnson, M. J. S. Dyer, S. Rule, M. Walker, et al. The impact of follicular lymphoma on health-related quality of life Ann. Onc., March 1, 2008; 19(3): 570 - 576. [Abstract] [Full Text] [PDF] M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma Ann. Onc., March 1, 2008; 19(3): 553 - 559. [Abstract] [Full Text] [PDF] S. Montoto, C. Moreno, E. Domingo-Domenech, C. Estany, A. Oriol, A. Altes, J. Besalduch, C. Pedro, S. Gardella, L. Escoda, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma Haematologica, February 1, 2008; 93(2): 207 - 214. [Abstract] [Full Text] [PDF] J. W. Friedberg, P. Cohen, L. Chen, K. S. Robinson, A. Forero-Torres, A. S. La Casce, L. E. Fayad, A. Bessudo, E. S. Camacho, M. E. Williams, et al. Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study J. Clin. Oncol., January 10, 2008; 26(2): 204 - 210. [Abstract] [Full Text] [PDF] A. Krishnan, A. Nademanee, H. C. Fung, A. A. Raubitschek, A. Molina, D. Yamauchi, R. Rodriguez, R. T. Spielberger, P. Falk, J. M. Palmer, et al. Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma J. Clin. Oncol., January 1, 2008; 26(1): 90 - 95. [Abstract] [Full Text] [PDF] M. Federico, C. Guglielmi, S. Luminari, C. Mammi, L. Marcheselli, U. Gianelli, A. Maiorana, F. Merli, M. Bellei, S. Pozzi, et al. Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study Haematologica, November 1, 2007; 92(11): 1482 - 1488. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789. [Abstract] [Full Text] [PDF] X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood, October 1, 2007; 110(7): 2569 - 2577. [Abstract] [Full Text] [PDF] P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s. [Abstract] [Full Text] [PDF] C. E. Dearden Role of antibody therapy in lymphoid malignancies Br. Med. Bull., September 1, 2007; 83(1): 275 - 290. [Abstract] [Full Text] [PDF] W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al. Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF] A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559. [Abstract] [Full Text] [PDF] S. Montoto, A. J. Davies, J. Matthews, M. Calaminici, A. J. Norton, J. Amess, S. Vinnicombe, R. Waters, A. Z.S. Rohatiner, and T. A. Lister Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma J. Clin. Oncol., June 10, 2007; 25(17): 2426 - 2433. [Abstract] [Full Text] [PDF] M. H.J. van Oers Rituximab maintenance therapy: a step forward in follicular lymphoma Haematologica, June 1, 2007; 92(6): 826 - 833. [Abstract] [Full Text] [PDF] J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF] M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study J. Clin. Oncol., May 20, 2007; 25(15): 1986 - 1992. [Abstract] [Full Text] [PDF] H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, May 2, 2007; 99(9): 706 - 714. [Abstract] [Full Text] [PDF] S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) Haematologica, May 1, 2007; 92(5): 627 - 634. [Abstract] [Full Text] [PDF] S Wohrer, M Troch, J Zwerina, G Schett, C Skrabs, A Gaiger, U Jaeger, C. Zielinski, and M Raderer Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases Ann. Onc., April 1, 2007; 18(4): 647 - 651. [Abstract] [Full Text] [PDF] C. Nabhan It Is Follicular... . So, Why CHOP? J. Clin. Oncol., March 1, 2007; 25(7): 915 - 916. [Full Text] [PDF] A. J. Stel, B. ten Cate, S. Jacobs, J. W. Kok, D. C. J. Spierings, M. Dondorff, W. Helfrich, H. C. Kluin-Nelemans, L. F. M. H. de Leij, S. Withoff, et al. Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis J. Immunol., February 15, 2007; 178(4): 2287 - 2295. [Abstract] [Full Text] [PDF] E Nitta, K Izutsu, T Sato, Y Ota, K Takeuchi, A Kamijo, K Takahashi, K Oshima, Y Kanda, S Chiba, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study Ann. Onc., February 1, 2007; 18(2): 364 - 369. [Abstract] [Full Text] [PDF] C Nickenig, M Dreyling, E Hoster, W-D Ludwig, B Dorken, M Freund, C Huber, A Ganser, L Trumper, R Forstpointner, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group Ann. Onc., January 1, 2007; 18(1): 136 - 142. [Abstract] [Full Text] [PDF] G. A. Salles Clinical Features, Prognosis and Treatment of Follicular Lymphoma Hematology, January 1, 2007; 2007(1): 216 - 225. [Abstract] [Full Text] [PDF]